Filing Flows › Nutra Pharma (NPHC) › Q4 2025
Nutra Pharma (NPHC) Q4 2025 earnings results (fourth quarter 2025)
10-K filed May 20, 2026
Nutra Pharma (NPHC) reported revenue of $29K for the fourth quarter 2025 (Q4 2025), -65% from a year earlier and -59% from the quarter before.
Nutra Pharma, Q4 2025: revenue $29K (-65% year over year), net loss $489K, operating cash flow −$220K. The chart follows the revenue to costs, profit and cash.
| Q4 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $29K | -59% | -65% |
| Operating profit | −$466K | — | — |
| Net earnings | −$489K | — | — |
| Operating cash flow | −$220K | — | — |
What changed
Revenue was $29K in Q4 2025, down 65% year over year and down 59% from the previous quarter.
Operating costs exceeded revenue by $466K, an operating margin of -1614.2%. Total costs grew 90% against a revenue fall of 65%. The quarter ended with a net loss of $489K, narrower than the previous quarter's $524K loss.
Operating cash flow was −$220K. Non-cash charges added back $3K of depreciation and $16K of share-based compensation. Working capital and other items added $250K.
Questions
What was Nutra Pharma's revenue in the fourth quarter 2025?
Nutra Pharma (NPHC) reported revenue of $29K for the fourth quarter 2025 (Q4 2025), -65% from a year earlier and -59% from the quarter before.
Source: Nutra Pharma 10-K on SEC EDGAR.